FdaApplication
NDA 217603
Identifiers
- fda_app_no: NDA217603
Properties
| Property | Value |
|---|---|
| applicant_name | TARSUS PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2023-07-24 |
Revenue by product
XDEMVY
| Period | Revenue |
|---|---|
| Q2 2026 | $173.9M |
| Q1 2026 | $145.4M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| XDEMVY | LOTILANER | 0.25% | SOLUTION/DROPS;OPHTHALMIC |
1 product